Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection

Hisham Abdel-Azim; Kris Michael Mahadeo; Quan Zhao; Sajad Khazal; Donald B. Kohn; Gay M. Crooks; Ami J. Shah; Neena Kapoor

doi:10.1002/ajh.24141

Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection

Hisham Abdel-Azim, Kris Michael Mahadeo, Quan Zhao, Sajad Khazal, Donald B. Kohn, Gay M. Crooks, Ami J. Shah, Neena Kapoor

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1021-1026
Number of pages	6
Journal	American Journal of Hematology
Volume	90
Issue number	11
DOIs	https://doi.org/10.1002/ajh.24141
State	Published - Nov 2015
Externally published	Yes

ASJC Scopus Subject Areas

Hematology

Keywords

Cyclophosphamide/therapeutic use
Genetic Diseases, Inborn/drug therapy
Cyclosporine/therapeutic use
Humans
Child, Preschool
Infant
Male
Tacrolimus/therapeutic use
Myeloablative Agonists/therapeutic use
Graft vs Host Disease/genetics
HLA Antigens/genetics
Transplantation, Homologous
Graft Rejection/genetics
Female
Unrelated Donors
Child
Gene Expression
Vidarabine/analogs & derivatives
Drug Administration Schedule
Antibodies, Monoclonal, Humanized/therapeutic use
Busulfan/therapeutic use
Hematopoietic Stem Cell Transplantation
Alemtuzumab
Methylprednisolone/therapeutic use
Pilot Projects
Adolescent
Survival Analysis
Immunosuppressive Agents/therapeutic use
Transplantation Conditioning

Access to Document

10.1002/ajh.24141

OpenUrl availability

Full text

Cite this

Abdel-Azim, H., Mahadeo, K. M., Zhao, Q., Khazal, S., Kohn, D. B., Crooks, G. M., Shah, A. J., & Kapoor, N. (2015). Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. American Journal of Hematology, 90(11), 1021-1026. https://doi.org/10.1002/ajh.24141

Research output: Contribution to journal › Article › peer-review

Abdel-Azim, H, Mahadeo, KM, Zhao, Q, Khazal, S, Kohn, DB, Crooks, GM, Shah, AJ & Kapoor, N 2015, 'Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection', American Journal of Hematology, vol. 90, no. 11, pp. 1021-1026. https://doi.org/10.1002/ajh.24141

Abdel-Azim H, Mahadeo KM, Zhao Q, Khazal S, Kohn DB, Crooks GM et al. Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. American Journal of Hematology. 2015 Nov;90(11):1021-1026. doi: 10.1002/ajh.24141

Abdel-Azim, Hisham ; Mahadeo, Kris Michael ; Zhao, Quan et al. / Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases : An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. In: American Journal of Hematology. 2015 ; Vol. 90, No. 11. pp. 1021-1026.

@article{b00dfa42087a4fcf9e2a609d67af7d39,

title = "Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection",

keywords = "Cyclophosphamide/therapeutic use, Genetic Diseases, Inborn/drug therapy, Cyclosporine/therapeutic use, Humans, Child, Preschool, Infant, Male, Tacrolimus/therapeutic use, Myeloablative Agonists/therapeutic use, Graft vs Host Disease/genetics, HLA Antigens/genetics, Transplantation, Homologous, Graft Rejection/genetics, Female, Unrelated Donors, Child, Gene Expression, Vidarabine/analogs & derivatives, Drug Administration Schedule, Antibodies, Monoclonal, Humanized/therapeutic use, Busulfan/therapeutic use, Hematopoietic Stem Cell Transplantation, Alemtuzumab, Methylprednisolone/therapeutic use, Pilot Projects, Adolescent, Survival Analysis, Immunosuppressive Agents/therapeutic use, Transplantation Conditioning",

author = "Hisham Abdel-Azim and Mahadeo, {Kris Michael} and Quan Zhao and Sajad Khazal and Kohn, {Donald B.} and Crooks, {Gay M.} and Shah, {Ami J.} and Neena Kapoor",

note = "Publisher Copyright: {\textcopyright} 2015 Wiley Periodicals, Inc.",

year = "2015",

month = nov,

doi = "10.1002/ajh.24141",

language = "English",

volume = "90",

pages = "1021--1026",

journal = "American Journal of Hematology",

issn = "0361-8609",

number = "11",

}

TY - JOUR

T1 - Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases

T2 - An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection

AU - Abdel-Azim, Hisham

AU - Mahadeo, Kris Michael

AU - Zhao, Quan

AU - Khazal, Sajad

AU - Kohn, Donald B.

AU - Crooks, Gay M.

AU - Shah, Ami J.

AU - Kapoor, Neena

PY - 2015/11

Y1 - 2015/11

KW - Cyclophosphamide/therapeutic use

KW - Genetic Diseases, Inborn/drug therapy

KW - Cyclosporine/therapeutic use

KW - Humans

KW - Child, Preschool

KW - Infant

KW - Male

KW - Tacrolimus/therapeutic use

KW - Myeloablative Agonists/therapeutic use

KW - Graft vs Host Disease/genetics

KW - HLA Antigens/genetics

KW - Transplantation, Homologous

KW - Graft Rejection/genetics

KW - Female

KW - Unrelated Donors

KW - Child

KW - Gene Expression

KW - Vidarabine/analogs & derivatives

KW - Drug Administration Schedule

KW - Antibodies, Monoclonal, Humanized/therapeutic use

KW - Busulfan/therapeutic use

KW - Hematopoietic Stem Cell Transplantation

KW - Alemtuzumab

KW - Methylprednisolone/therapeutic use

KW - Pilot Projects

KW - Adolescent

KW - Survival Analysis

KW - Immunosuppressive Agents/therapeutic use

KW - Transplantation Conditioning

UR - http://www.scopus.com/inward/record.url?scp=84944532297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944532297&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/82607f33-a51f-3e90-88fd-0905a12db878/

U2 - 10.1002/ajh.24141

DO - 10.1002/ajh.24141

M3 - Article

C2 - 26242764

AN - SCOPUS:84944532297

SN - 0361-8609

VL - 90

SP - 1021

EP - 1026

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 11

ER -

Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection

ASJC Scopus Subject Areas

Keywords

Access to Document

OpenUrl availability

Other files and links

Cite this